Michael Perry

Dr Michael Perry is senior vice president and chief scientific officer of Global Business Development and Licensing for Novartis AG. From 2014 to 2016, Dr Perry was chief scientific officer of Novartis’ Cell and Gene Therapy Unit, and from 2012 to 2014 was vice president and global head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a US affiliate of Switzerland-based Novartis AG. Dr Perry, based in the United States, was also global head of R&D at Baxter Healthcare, president and chief executive of Cell & Gene Therapy at Novartis affiliates Systemix and Genetic Therapy, vice president of regulatory affairs at Sandoz Pharmaceuticals, director of regulatory affairs at Schering-Plough Corporation, chair and chief executive of several early stage biotech companies. He also previously served as a Venture Partner with Bay City Capital, based in San Francisco California.
Bio last updated 04 Dec 2019

Article Timeline

Network Graph

Displaying all related organisations and their related contacts. Hover over a node to display a link to the BNiQ page for that person or organisation.

Access to our data for Michael Perry is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

Michael Perry is linked to 2 organisations which are included in 1 list - Public Companies - non WA.

To see the data you will need to .

Total Shareholder Return as at 29/05/20

1 year TSR5 year TSR
315thAvita Medical10%48%
671 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®


Chief Executive
Year started and most recent title

Share Transactions

$0 Bought
$5k Issued
Total value as at the date of the transaction
Powered by Morningstar ®


th-Avita Medical$16.4m
76 listed non wa companies ranked by revenue.
Powered by Morningstar ®